BioLife Solutions, Inc.

NASDAQ:BLFS

Medical - Instruments & Supplies

Healthcare
$38.61 +1.56%

+$0.40 today

Market cap
$1.89B
Beta
1.97
P/E (TTM)
-119.9
EPS (TTM)
-$0.22
52W Low $17.86High $29.62

Volume 4.39M

Average 0.52M

BLFS Stock-Based Compensation

Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.

BioLife Solutions, Inc.NASDAQ: BLFS

Stock-Based Compensation · Q1 FY2026 · quarter ended Mar 2026

Stock-based compensation growth accelerates

Q1 FY2026 stock-based compensation of $4.81M rose 15.7% year over year, ahead of the -18.2% change in trailing-twelve-month stock-based compensation. Sequentially, it fell 32.1% from the prior quarter. Over 3 fiscal years it compounded at -3.2% a year.

Context

  • Stock-based compensation amounted to 23.9% of revenue in FY2025, down 13.7 pp from a year earlier.
  • Stock-based compensation increased in 1 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +15.7% holds above the trailing-twelve-month pace of -18.2%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$4.81M-32.1% QoQ
Last fiscal yearDec 2025
$22.99M-25.6% YoY
LTMMar 2026
$23.65M-18.2% YoY
Stock-Based Compensation past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+15.7%——
1 year-25.6%——
3-year CAGR-3.2%——
5-year CAGR——
10-year CAGR——

Stock-Based Compensation history

USD · from the cash flow

Latest · FY2025
22.99M USD
Year-over-year change
-25.6%
4-year CAGR
+13.3%

Stock-Based Compensation vs competitors

How BLFS compares with its peers on the latest reported figures

  • BLFS's LTM Mar 2026 stock-based compensation of $23.65M is the 6th largest of the 11 companies compared; the peer median is $23.43M.
  • Its year-over-year change of -18.2% is the 6th highest of 11, against a peer median of -19.6%.
  • Stock-based compensation amounts to 23.7% of revenue for BLFS, versus a peer median of 9.2%.
BLFS Competitors Peer median
Stock-Based Compensation for BLFS and competitors
Company Period LTM YoY 3-year CAGR% of revenue
NVCRNovoCure LimitedLTM Mar 2026$118.47M -23.8%—17.6%
PHRPhreesia, Inc.LTM Apr 2026$63.78M -5.3%+4.7%12.9%
ATRCAtriCure, Inc.LTM Jun 2026$47.27M +13.2%+15.8%8.3%
KMTSKestra Medical Technologies, Ltd.LTM Jan 2026$45.65M +1845.1%—54.5%
STAASTAAR Surgical CompanyLTM Apr 2026$29.4M +9.3%+14.5%10.1%
BLFSBioLife Solutions, Inc.LTM Mar 2026$23.65M -18.2%-3.2%23.7%
PLSEPulse Biosciences, Inc.LTM Jun 2026$17.47M -15.4%+60.5%1474.4%
AZTAAzenta, Inc.LTM Sep 2026$12.24M -41.4%+9.3%2.0%
HROWHarrow Health, Inc.LTM Mar 2026$11.78M -34.6%+16.2%4.4%
NEOGNeogen CorporationLTM Aug 2026$11.54M -36.9%+9.6%1.3%
ESTAEstablishment Labs Holdings Inc.LTM Sep 2026$6.28M -31.7%—2.4%
Peer median (excluding BLFS) $23.43M-19.6%+14.5%9.2%

Competitors are the stored peer set for BLFS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(7.64M)(139.81M)(66.43M)(20.18M)(4.6M)
Depreciation & Amortization12.87M16.47M12.3M5.49M4.69M
Deferred Income Tax(20.13M)(5.24M)(62K)(64K)65K
Stock-Based Compensation13.96M25.33M31.67M30.92M22.99M
Change in Working Capital(2.26M)(14.91M)1.47M227K(8.91M)
Accounts Receivables(10.13M)(10.75M)15.35M(2.9M)264K
Inventory114K(6.56M)(8.55M)781K(1.27M)
Accounts Payables2.02M414K(8.43M)26K(2.09M)
Other Working Capital5.74M1.99M3.09M2.32M(5.82M)
Other Non-Cash Items(1.64M)109.65M8.56M(7.96M)5.87M
Operating Cash Flow(4.84M)(8.49M)(12.5M)8.43M20.12M
Capital Expenditures(8.39M)(10.39M)(6.38M)(3.23M)(9.48M)
Acquisitions (Net)1.56M0060.39M23.52M
Purchases of Investments(6.37M)(53.12M)(27.1M)(18.42M)(127.17M)
Sales of Investments6.37M8.92M56.17M21.92M41.59M
Other Investing Activities(5.82M)(3.54M)(4.86M)(2.37M)0
Investing Cash Flow(12.64M)(58.12M)17.84M58.3M(71.54M)
Debt Repayment(2.89M)17.84M(498K)(6.61M)(10M)
Common Stock Issued1.27M192K10.24M202K18K
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities(1.16M)(1.71M)845K(377K)(942K)
Financing Cash Flow(2.78M)16.32M10.59M(6.78M)(10.92M)
Effect of Forex Changes(282K)(108K)35K00
Net Change in Cash(20.59M)(50.4M)15.97M59.95M(62.35M)
Free Cash Flow(13.22M)(18.87M)(18.88M)5.2M10.64M

BioLife Solutions, Inc.

NASDAQ:BLFS

Intrinsic Alpha fair value

Locked

Current Price

$38.61

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.